Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study

BACKGROUND: Epacadostat, an oral, selective inhibitor of IDO1, has shown activity when administered with pembrolizumab. We evaluated the addition of chemotherapy to epacadostat and pembrolizumab in patients with advanced or metastatic solid tumors. One proposed mechanism of resistance to PD-1 checkp...

Descripción completa

Detalles Bibliográficos
Autores principales: Powderly, John D, Klempner, Samuel J, Naing, Aung, Bendell, Johanna, Garrido-Laguna, Ignacio, Catenacci, Daniel V T, Taylor, Matthew H, Lee, James J, Zheng, Fred, Zhou, Feng, Gong, Xiaohua, Gowda, Hema, Beatty, Gregory L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632315/
https://www.ncbi.nlm.nih.gov/pubmed/36156099
http://dx.doi.org/10.1093/oncolo/oyac174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632315/
https://www.ncbi.nlm.nih.gov/pubmed/36156099
http://dx.doi.org/10.1093/oncolo/oyac174

Ejemplares similares